IADR Abstract Archives
Probiotic-Based Antifungal Formulation For Oral Candida albicans Infections
Objectives: Candida albicans is a major fungal pathogen in humans which causes superficial mucosal infections as well as systemic mycoses with higher morbidity and mortality. Adverse effects of current antifungal regimes and alarming rise in drug resistance highlight the need for adjunctive therapies with better efficacy and minimal toxicity. The present study examined the efficacy of probiotic-based antifungal formulation on oral Candida infections. The primary objective of this study was to explore the antifungal potential of the cell free supernatant of oral probiotic bacteria L.plantarum 108 against Candida albicans.
Methods: Lactobacillus plantarum 108 strain was selected after a preliminary screen. The cell-free culture supernatant (CFS) of this probiotic strain was first used to examine its antifungal activity against planktonic and biofilm modes of C. albicans. Thereafter, the CFS was fractionated using graded-molecular weight cut-off filters of sizes 10 kDa, 5 kDa, 3 kDa, the fractions thus derived were used to test the antifungal activity. L. plantarum was also cultured under various pH and temperature to test the effect of culture-conditions on the antifungal activity of the supernatant. LDH assay was used to test the cytotoxicity of the probiotic products against human primary oral keratinocytes.
Results: Probiotic CFS demonstrated promising antifungal activity against both planktonic and biofilm mode of growth of C. albicans compared to the control samples (p<0.05). Microscopic analysis revealed that the CFS inhibits the yeast-to-hyphal transformation of C. albicans. Moreover, fractionation products retained the antifungal activity, which was independent of the initial pH of medium. LDH assay showed minimal cytotoxicity to human oral keratinocytes.
Conclusions: The present study demonstrated the therapeutic efficacy of probiotic-based antifungal formulation for Candida albicans.
Methods: Lactobacillus plantarum 108 strain was selected after a preliminary screen. The cell-free culture supernatant (CFS) of this probiotic strain was first used to examine its antifungal activity against planktonic and biofilm modes of C. albicans. Thereafter, the CFS was fractionated using graded-molecular weight cut-off filters of sizes 10 kDa, 5 kDa, 3 kDa, the fractions thus derived were used to test the antifungal activity. L. plantarum was also cultured under various pH and temperature to test the effect of culture-conditions on the antifungal activity of the supernatant. LDH assay was used to test the cytotoxicity of the probiotic products against human primary oral keratinocytes.
Results: Probiotic CFS demonstrated promising antifungal activity against both planktonic and biofilm mode of growth of C. albicans compared to the control samples (p<0.05). Microscopic analysis revealed that the CFS inhibits the yeast-to-hyphal transformation of C. albicans. Moreover, fractionation products retained the antifungal activity, which was independent of the initial pH of medium. LDH assay showed minimal cytotoxicity to human oral keratinocytes.
Conclusions: The present study demonstrated the therapeutic efficacy of probiotic-based antifungal formulation for Candida albicans.